TIL News and Press, Instil Bio Inc. From 05/27/22

Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...

Gainers: Avadel Pharmaceuticals AVDL +61%. PMV Pharmaceuticals PMVP +25%. Alpha Tau Medical (DRTS) +18%. SIGA Technologies SIGA +18%. Allarity Therapeutics (ALLR) +17%. Losers: Iovance Biotherapeutics (IOVA) -54%. SpringWorks Therapeutics SWTX...

Instil Bio (NASDAQ:TIL) said U.S. Food and Drug Administration (FDA) cleared its application to start a phase 1 trial of ITIL-306 in patients with lung, kidney and ovarian cancers. Instil added that the FDA cleared of the Investigational New Drug (IND) application marks the company'...

FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and tumor control at th...

DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced results of genomic a...

Instil Bio press release (NASDAQ:TIL): Q1 Non-GAAP EPS of -$0.36. As of March 31, 2022, we had $61.5 million in cash and cash equivalents and $318.0 million in marketable securities For further details see: Instil Bio Non-GAAP EPS of -$0.36

Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022 Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022 Cash runway into 2024 through key clinical data expected in 2023 DALLAS, May 16, 2022 (GLOBE NEWSW...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Instil Bio press release (NASDAQ:TIL): Q4 GAAP EPS of -$0.43 misses by $0.05. As of December 31, 2021, cash and cash equivalents of $37.6 million and $416.5 million in marketable securities, compared to $241.7 million in cash and cash equivalents and no investments in mark...

- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate, ITIL-168, in melanoma - Expansion of manufacturing capacity in Manchester, UK...